Ageliki Karatza | Clinical Trials | Best Researcher Award

Prof. Dr. Ageliki Karatza | Clinical Trials | Best Researcher Award

University of Patras Medical School | Greece

Prof. Dr. Ageliki Karatza is a distinguished figure in the field of Paediatrics and Paediatric Cardiology, recognized for her exceptional academic achievements, clinical expertise, and research contributions spanning decades. Her journey began with her admission to the University of Patras Medical School through highly competitive national examinations, where she graduated with one of the top degrees in her class. Following her graduation, she completed her rural medical service before pursuing specialization in General Paediatrics, earning her board certification after extensive training and rigorous examinations.Her dedication to advancing paediatric care led her to prominent institutions in London, including Imperial College, Hammersmith and Queen Charlotte’s Hospitals, and the Royal Brompton Hospital, where she gained substantial clinical and research experience in Paediatric and Perinatal Cardiology. Her fellowship and registrar positions in Neonatal and Paediatric Cardiology enabled her to develop expertise in managing complex cardiovascular conditions in neonates, infants, and children. Upon returning to Greece, she held key positions in academic medicine at the University of Patras Medical School, progressing through roles as Clinical Lecturer, Senior Lecturer, Associate Professor, and ultimately achieving the rank of Professor in Paediatrics-Paediatric Cardiology.In addition to her teaching responsibilities, she has been instrumental in organizing and delivering undergraduate and postgraduate education, serving as a tutor in multiple master’s programs and teaching medical students and trainees at various levels. Her role as the ERASMUS representative in Paediatrics has facilitated international academic collaborations and student exchanges, strengthening the global reach of the University of Patras Medical School. Clinically, she has been responsible for the Paediatric Cardiology outpatient clinic, providing daily consultations and urgent care services for the entire Southwestern Greece region, ensuring that paediatric patients receive timely and specialized cardiac care.

Profile: Google Scholar

Featured Publications

Karatza, A. A., Wolfenden, J. L., Taylor, M. J. O., Wee, L., Fisk, N. M., & Gardiner, H. M. (2002). Influence of twin-twin transfusion syndrome on fetal cardiovascular structure and function: Prospective case–control study of 136 monochorionic twin pregnancies. Heart, 88(3), 271–277.

Karatza, A. A., Bush, A., & Magee, A. G. (2005). Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. International Journal of Cardiology, 100(2), 267–273.

Davlouros, P. A., Karatza, A. A., Gatzoulis, M. A., & Shore, D. F. (2004). Timing and type of surgery for severe pulmonary regurgitation after repair of tetralogy of Fallot. International Journal of Cardiology, 97, 91–101.

Gardiner, H. M., Taylor, M. J. O., Karatza, A., Vanderheyden, T., Huber, A., … (2003). Twin-twin transfusion syndrome: The influence of intrauterine laser photocoagulation on arterial distensibility in childhood. Circulation, 107(14), 1906–1911.

Fouzas, S., Karatza, A. A., Davlouros, P. A., Chrysis, D., Alexopoulos, D., … (2014). Neonatal cardiac dysfunction in intrauterine growth restriction. Pediatric Research, 75(5), 651–657.

Karatza, A. A., Giannakopoulos, I., Dassios, T. G., Belavgenis, G., Mantagos, S. P., … (2011). Periconceptional tobacco smoking and isolated congenital heart defects in the neonatal period. International Journal of Cardiology, 148(3), 295–299.

Tsintoni, A., Dimitriou, G., & Karatza, A. A. (2020). Nutrition of neonates with congenital heart disease: Existing evidence, conflicts, and concerns. The Journal of Maternal-Fetal & Neonatal Medicine, 33(14), 2487–2492.

Anthracopoulos, M., Karatza, A., Liolios, E., Triga, M., Triantou, K., & Priftis, K. (2001). Prevalence of asthma among schoolchildren in Patras, Greece: Three surveys over 20 years. Thorax, 56(7), 569–571.

Vibeke Strand | Clinical Trials | Best Researcher Award

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents